Accelerate Diagnostics (Accelerate Diagnostics) Debt-to-Equity : -1.97 (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Accelerate Diagnostics Debt-to-Equity?

Accelerate Diagnostics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.29 Mil. Accelerate Diagnostics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $36.93 Mil. Accelerate Diagnostics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-19.89 Mil. Accelerate Diagnostics's debt to equity for the quarter that ended in Dec. 2023 was -1.97.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Accelerate Diagnostics's Debt-to-Equity or its related term are showing as below:

AXDX' s Debt-to-Equity Range Over the Past 10 Years
Min: -18.17 Med: -2.39 Max: 2.09
Current: -1.97

During the past 13 years, the highest Debt-to-Equity Ratio of Accelerate Diagnostics was 2.09. The lowest was -18.17. And the median was -2.39.

AXDX's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.21 vs AXDX: -1.97

Accelerate Diagnostics Debt-to-Equity Historical Data

The historical data trend for Accelerate Diagnostics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerate Diagnostics Debt-to-Equity Chart

Accelerate Diagnostics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-18.17

-2.39

-3.17

-3.48

-1.97

Accelerate Diagnostics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															-3.48	-2.02	-0.95	-1.04	-1.97

Competitive Comparison of Accelerate Diagnostics's Debt-to-Equity

For the Medical Devices subindustry, Accelerate Diagnostics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accelerate Diagnostics's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Accelerate Diagnostics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Accelerate Diagnostics's Debt-to-Equity falls into.

Accelerate Diagnostics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Accelerate Diagnostics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.286	+	36.934)	/	-19.888
	=	-1.97

Accelerate Diagnostics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.286	+	36.934)	/	-19.888
	=	-1.97

Accelerate Diagnostics (NAS:AXDX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Accelerate Diagnostics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Accelerate Diagnostics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerate Diagnostics (Accelerate Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accelerate Diagnostics Inc (NAS:AXDX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

AXDX:Mexico 1A80:Germany

Address

3950 South Country Club Road, Suite 470, Tucson, AZ, USA, 85714

Website

https://www.acceleratediagnostics.com

Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.

Executives

David Patience	officer: Chief Financial Officer	C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 240, TUCSON AZ 85714
Jack Phillips	director, officer: PRESIDENT AND CEO	11731 YALE DR, CARMEL IN 46032
Larry Michael Mertz	officer: Chief Technology Officer	3950 S. COUNTRY CLUB ROAD, TUCSON AZ 85714
Marran H. Ogilvie	director	599 LEXINGTON AVENUE, NEW YORK NY 10022
Jennifer Regan	director	C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714
Mark S. Black	director	3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714
Steven Reichling	officer: CFO	7000 NORTH BROADWAY, BUILDING 3-307, DENVER CO 80221
Ron Price	officer: SVP & HEAD OF COM OPS AMERICAS	3950 SOUTH COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714
Wayne Burris	director	3451 PLANO PARKWAY, LEWISVILLE TX 75056
Hany Massarany	director	1910 INNOVATION PARK DR, TUCSON AZ 85737
Jack W Schuler	director, 10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Mark C Miller	director	C/O STERICYCLE INC., 28161 N KEITH DRIVE, LAKE FOREST IL 60045
Ten Brink Frank Jm	director	C/O STERICYCLE INC, 28161 N KEITH DR, LAKE FOREST IL 60045
Charles M Watts	director	3950 SOUTH COUNTRY CLUB, SUITE 470, TUCSON AZ 85714
Louise Francesconi	director	870 WINTER STREET, WALTHAM MA 02451